Loading…
← CockpitCompetitor Analysis › CAPLIPOINT.NS Caplin Point LaboratoriesOpen in the cockpit ↗

Caplin Point LaboratoriesCAPLIPOINT.NSCompetitor analysis, valuation and peers

India · INR·Pharma & Healthcare›Pharmaceuticals: Major

Generic drug maker exporting formulations directly through its own distribution network in Latin America and Africa.

≈ A niche emerging-markets generics exporter with owned distributionMomentum weak 29
Mkt cap
$1.70B
US dollars, full cap
Free float
27%
of shares outstanding
$/day
$3.31M
20-day average traded
Fwd P/E
21.4×
forward earnings
ROIC−WACC
+3.7 pp
WACC 14.1%
Hurdle
+9 pp
Req g minus delivered
Next earnings
79 days
5 Feb 2027
Close · INR₹2,085
1D-7.2%
1W-17.3%
1M-7.7%
3M-17.6%
6M+2.3%
YTD+13.4%
1Y+7.2%
ATR %4.8%
Beta0.73
52w lowhigh30.3% off high

What Caplin Point Laboratories does

Generic drug maker exporting formulations directly through its own distribution network in Latin America and Africa.

Sells through its own distribution companies across Latin America, so it keeps the distributor margin, supplying pharmacies and hospitals directly. In recent years the US sterile-injectable business, built through its Caplin Steriles unit, has become a second leg.

In one line: A niche emerging-markets generics exporter with owned distribution.

Products and services

  • Branded generic exports
  • Sterile injectables (US)
  • Institutional/tender sales

Customers

  • Latin American pharmacies/distributors (own networ
  • US injectable market

Where it sits in the supply chain

  • Formulation manufacturing
  • Own distribution network (Latin…
  • Sterile injectables (Caplin Steriles)

What could go right

  • Latin America pharmacy network growth
  • US sterile injectable approvals

What could go wrong

  • Latin American currency/political risk
  • US FDA inspection risk

Moat: narrow (distribution, regulatory licence). Owned last-mile distribution in Latin America is unusual and hard for rivals to replicate quickly.

Headquarters: Chennai, India · Founded: 1990 · Employees: 5,455

Named competitors

Caplin Point Laboratories at a glance

Size Caplin Point Laboratories (CAPLIPOINT.NS) is an India Health Care company (Pharmaceuticals: Major) with a market value of $1.70B, the 428th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹2,085 on 18 Nov 2026.

Performance Over six months the shares gained 2.3%, against +1.7% for the median peer and +3.8% for the India market (cap-weighted) — 9th highest of 20 in its peer set.

Growth Revenue grew 16.8% over the last twelve months (peer median +6.8%); the operating margin is 31.4% (peer median 9.9%).

Valuation It trades at 21.4× forward earnings against a peer median of 21.0× (8th most expensive of 16).

Price implies For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 3.7 points above its cost of capital (14.1% WACC).

Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026CAPLIPOINT.NS 103Peer median 103
Six months, rebased to 100: Caplin Point Laboratories against the median of its 20 peers (local-currency closes).

Caplin Point Laboratories financials

Reported figures in INR; fiscal year ends 2026-03-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue₹23.8B₹21.7B₹19.2B₹16.8B₹14.5B
Revenue growth—+13%+15%+15%—
Gross profit₹11.4B₹9.49B₹8.22B₹6.82B₹5.58B
EBITDA₹8.31B₹7.58B₹6.41B₹5.41B₹4.34B
Net income₹6.89B₹6.41B₹5.36B₹4.57B₹3.76B
Free cash flown/a₹3.25B₹2.92B₹2.16B₹1.04B
Capital expendituren/a₹2.48B₹1.92B₹1.46B₹1.93B
Total debt₹46.2M₹46.1M₹50.2M₹19.7M₹54.8M

Quarterly statements and history in the cockpit →

Caplin Point Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+100%+200%-20%0%+20%300723600993FAEMAZEINDGN688166300357NATCOPHARM1681AGIO9989600664ASTRAZENETONANURAS3933301047CAPLIPOINT.NS6-month return →1-month return →
Up and to the right = strong over both horizons. Caplin Point Laboratories is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%20×40×60×80×300723600993FAEINDGN688166300357NATCOPHARM16819989600664ETONANURAS3933301047CAPLIPOINT.NSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Caplin Point Laboratories is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%300723600993INDGN300357ETON301047CAPLIPOINT.NSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Caplin Point Laboratories is the large dot.

Caplin Point Laboratories competitors and peer comparison

Head to head with its named competitors (CAPLIPOINT.NS vs NATCOPHARM.NS vs STAR.NS vs MARKSANS.NS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Caplin Point Laboratories CAPLIPOINT.NS$1.70B+2%+17%31%21.4×24.3%
NATCO Pharma NATCOPHARM.NS$1.73B-27%-30%17%19.1×20.5%
Strides Pharma Science STAR.NS$946M-17%+11%14%15.9×17.6%
Marksans Pharma MARKSANS.NS$1.43B+36%+24%20%23.2×31.0%

How Caplin Point Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Caplin Point Laboratories against its 20 peers (data as of 18 Nov 2026)
MeasureCAPLIPOINT.NSPeer medianRank in peer set
1-month return-7.7%-0.5%8th lowest of 21
6-month return+2.3%+1.7%9th highest of 20
Distance from 52-week high-30.3%-35.8%8th highest of 21
Revenue growth (TTM)+16.8%+6.8%8th highest of 20
Operating margin31.4%9.9%3rd highest of 20
Forward P/E21.4×21.0×8th most expensive of 16
Growth the price implies (Req g, 7 yrs)24.3%14.8%6th most demanding of 17
Growth delivered (Del g)+15.7%+8.7%5th highest of 17
Hurdle (Req g minus delivered)+8.6 pp+1.8 pp6th most demanding of 17
ROIC minus cost of capital+3.7 pp-2.7 pp7th highest of 21
EV / EBITDA18.1×21.5×4th cheapest of 9
Net debt / EBITDA-1.1×-1.1×5th least indebted of 9

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Caplin Point Laboratories CAPLIPOINT.NSIndia$1.70B+2%+17%31%21.4×24.3%+15.7%
ApicHope Pharmaceutical 300723.SZChina$1.70B-36%-28%-50%22.0×11.3%-11.0%
Mayinglong Pharmaceutical 600993.SSChina$1.70B+2%+7%17%17.0×-3.5%+6.8%
Faes Farma FAE.MCSpain$1.71B+6%+32%14%17.4×3.7%+9.9%
Maze Therapeutics MAZEUnited States$1.71B+27%-100%-821%n/an/an/a
Indegene INDGN.NSIndia$1.69B+28%+36%12%29.5×31.4%+29.4%
BrightGene Bio-Medical Technology 688166.SSChina$1.71B-57%+14%7%74.9×35.3%+9.2%
Zhejiang Wolwo Bio-Pharmaceutical 300357.SZChina$1.67B-12%+7%39%26.3×18.4%+10.8%
NATCO Pharma NATCOPHARM.NSIndia$1.73B-27%-30%17%19.1×20.5%+19.0%
Braveheart Bio BRVEUnited States$1.67Bn/an/an/an/an/an/a
Consun Pharmaceutical 1681.HKHong Kong$1.65B+8%+15%35%9.2×-14.9%+13.5%
Agios Pharmaceuticals AGIOUnited States$1.78B+4%+214%-298%n/an/an/a
Shenzhen Hepalink Pharmaceutical 9989.HKHong Kong$1.78B-13%-1%8%8.7×-0.4%-0.2%
Tonghua Golden-Horse Pharmaceutical Industry 000766.SZChina$1.62B-47%-18%9%n/a33.0%+0.9%
Harbin Pharmaceutical 600664.SSChina$1.78B+32%+2%5%19.7×-5.3%+8.2%
AstraZeneca Pharma India ASTRAZEN.NSIndia$1.62B-30%+30%10%n/a42.4%+23.0%
Eton Pharmaceuticals ETONUnited States$1.79B+226%+101%29%24.6×21.9%+359.6%
Anupam Rasayan India ANURAS.NSIndia$1.61B-3%+24%16%49.9×n/an/a
United Laboratories International 3933.HKHong Kong$1.80B-20%-13%5%13.0×1.2%+7.8%
Sino Biological 301047.SZChina$1.60B+27%+20%17%51.6×31.1%-15.1%
Qingdao Baheal Medical 301015.SZChina$1.81B+2%-6%8%21.0×10.1%+5.0%

Questions

Who are Caplin Point Laboratories's main competitors?
Named competitors: Natco Pharma (NATCOPHARM.NS), Strides Pharma (STAR.NS), Marksans Pharma (MARKSANS.NS). The cockpit's measured peer set (industry) also includes ApicHope Pharmaceutical (300723.SZ), Mayinglong Pharmaceutical (600993.SS), Faes Farma (FAE.MC), Maze Therapeutics (MAZE), Indegene (INDGN.NS), BrightGene Bio-Medical Technology (688166.SS).
Is Caplin Point Laboratories expensive compared with its peers?
On forward p/e it trades at 21.4× against a peer median of 21.0×, 8th most expensive of 16 in its peer set. For today's price to make sense, revenue must grow about 24% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Caplin Point Laboratories stock performed?
Over six months to 18 Nov 2026 the shares returned +2.3% against +1.7% for the median peer; over one year +7.2%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.